Jump to content

File:Antisense Oligonucleotide Use in ncRNA therapy.png

Page contents not supported in other languages.
This is a file from the Wikimedia Commons
From Wikipedia, the free encyclopedia

Antisense_Oligonucleotide_Use_in_ncRNA_therapy.png (720 × 504 pixels, file size: 90 KB, MIME type: image/png)

Summary

Description
English: ASO (Antisense oligonucleotide) are indicated as blue single stranded molecules in the cytoplasm. Double stranded siRNAs are indicated as a blue and red strand incorporated together. 1. Once they enter the nucleus, they undergo further modifications allowing them to bind to their target (lncRNA or mRNA) and degrade them using RNase H.The degradation of mRNA and lncRNA can be done through the use of siRNA in conjunction with RISC complexes found inside the cytoplasm or nucleus. ASOs can also be used to preferentially modulate processing of mRNA and lncRNA transcripts. The ASO has the ability to bind to pre-mRNA structure and directly modulate splicing (5), by masking splicing enhancer and repressors sequences, causing skipping in exons (2). It also has the ability to modulate polyadenylation selection in those transcripts with more than one polyA site in the 3'-UTR (6). We can also have the ASO binding to mRNA and sterically blocking the ribosomal subunits from translation into proteins (3), this can also be done using siRNA. In order to target ncRNAs within the nucleus we can also make use of viruses, which can be used to knockout (short RNA) shRNA or lncRNA (4), same vectors can also be used to upregulate lncRNA activity.
Date
Source Own work
Author KB-OKO

Licensing

I, the copyright holder of this work, hereby publish it under the following license:
w:en:Creative Commons
attribution share alike
This file is licensed under the Creative Commons Attribution-Share Alike 4.0 International license.
You are free:
  • to share – to copy, distribute and transmit the work
  • to remix – to adapt the work
Under the following conditions:
  • attribution – You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • share alike – If you remix, transform, or build upon the material, you must distribute your contributions under the same or compatible license as the original.

Captions

Diagramatic representation of the cell showing different ncRNA therapeutic approaches and their pathway.

Items portrayed in this file

depicts

4 March 2022

image/png

6df73dbf84144e15d83c025939e0386f410d617d

91,829 byte

504 pixel

720 pixel

File history

Click on a date/time to view the file as it appeared at that time.

Date/TimeThumbnailDimensionsUserComment
current22:03, 4 March 2022Thumbnail for version as of 22:03, 4 March 2022720 × 504 (90 KB)KB-OKONucleus change
21:49, 4 March 2022Thumbnail for version as of 21:49, 4 March 2022720 × 504 (93 KB)KB-OKOUploaded own work with UploadWizard

The following page uses this file:

Metadata